Treatment of Cutaneous Leishmaniasis with Liposomal Amphotericin B in the Elderly: A Randomized Clinical Trial
Year: 2025
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Abstract: The efficacy, best dosage, and safety of liposomal amphotericin B (LAB) in the treatment of cutaneous leishmaniasis (CL) caused by Leishmania braziliensis in elderly patients was determined by a randomized, controlled trial. We selected 28 patients of both sexes age 60 years old or older with CL diagnosis confirmed by detection of L. braziliensis DNA. The groups were treated with different total doses of LAB (group 1: 12 mg/kg; group 2: 18 mg/kg; and group 3: 24 mg/kg). Clinical and laboratory evaluations were carried out during a period of 180 days (day 0, day 15, day 30, day 60, day 90, and day 180). The highest cure rate (89%) was in group 3 (differences were not statistically significant) along with the lowest incidence of side effects (11%), suggesting that 24 mg/kg is the best dose of LAB to treat CL in elderly patients.
Institutions: Universidade Federal da Bahia, Universidade Federal da Paraíba, Complexo Hospitalar Universitário Professor Edgard Santos, Conselho Nacional de Desenvolvimento Científico e Tecnológico, Universidade Federal do Recôncavo da Bahia, Instituto Nacional de Ciência e Tecnologia de Doenças Tropicais
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4415881806